Is Amarin Corp (AMRN) poised for a bounce?
Amarin presented final results of the EVAPORATE Trial at European Society of Cardiology Congress annual meeting on August 29, 2020. The VASCEPA® (Icosapent Ethyl) reported to significantly reduce Coronary Plaque by 17% . The plaque causes coronary arteries to narrow, limiting blood flow to the heart causing heart failure, death and so on. This is a new discovery for which the company was doing the trials for last 18 months. My blog reader may recall that, I had written the following in my February 2019 blog . Amarin's drug "VASCEPA" had these wonderful results: Cardiovascular Death Reduced by 20% Fatal or Nonfatal Heart Attacks Reduced by 31% Fatal or Nonfatal Stroke Reduced by 28% Urgent or Emergent Coronary Revascularization Reduced by 35% Actually the science behind this drug has produced outstanding results. Based on this, I had added it as one of may favorite stock for 2020. However, so far it has been a disappointment due to AMRN's court battle with generics. T...